What we do Venus Remedies Ltd is a pharmaceutical company specializing in anti-infectives, oncology, neurology, pain management, and skin care, with global injectable drug manufacturing and R&D expertise. |
Founded in 1,989 |
Market share A significant player in injectable pharmaceuticals with a global presence, known for pioneering pediatric and specialized formulations. |
Problem solved Addresses global healthcare needs with innovative injectables and treatments for infections, cancer, neurological and skin conditions, tackling antimicrobial resistance. |
Top clients or who we serve Serves global healthcare providers, hospitals, and pharmacies, focusing on B2B pharmaceutical markets and emerging consumer healthcare sectors. |
Key management - |
Our journey and innovations Founded in 1989, key milestones include WHO-GMP certification, German-GMP acquisition, innovative pediatric injectables, and launch of patented antibiotics and oncology drugs. |
Where we operate Operations primarily in India with manufacturing in Panchkula and Baddi; international presence via subsidiaries in Germany and Hungary; exports worldwide. |
Top products or what we offer Injectables and IV fluids in anti-infectives, oncology, neurology, pain management, specialized antibiotics such as Meropenem and patented ELORES. |
Top brands ELORES (US patent protected antibiotic), Meropenem pediatric dosage, Taxedol (oncology drug), R3SET (pain management), and Venpocare (wound healing). |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue mainly recurring through pharmaceutical product sales with steady demand in chronic and critical care segments. |
Our industry position Recognized leader in injectable and specialty formulations with strong R&D pipeline and adherence to global pharmaceutical standards. |
Financial highlights FY2025 standalone revenue ₹639.46 crore (11.17% growth), profit after tax ₹52.56 crore (72.34% growth), demonstrating robust financial performance. |
Geographical revenue split - |
Order book - |
Whats driving growth Innovation in high-value molecules, expanding product portfolio, digital transformation, and focus on combating antimicrobial resistance fuel growth. |
Our future plans Launching new specialized drugs, expanding consumer healthcare products, enhancing manufacturing via automation and digital tools, and environmental sustainability projects. |
Our green promise ISO 14064-1 certified, reduced carbon emissions, wastewater recycling, green initiatives including solar and rainwater harvesting projects underway. |
Our people and values Strong emphasis on safety, employee health programs, diversity, workplace harassment prevention policies, and fostering a supportive work environment. |
Key challenges ahead Managing regulatory complexities, antimicrobial resistance, market competition, and sustaining R&D investments. |
Interesting facts First in India to launch pediatric Meropenem injection; established patented antibiotic combating superbugs; innovative product pipeline globally recognized. |
Risks and strategy Mitigates risks with robust internal controls, diversified product portfolio, proactive regulatory compliance, and continuous innovation. |
